Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

The Geneva Risk Score estimates a medical inpatient’s likelihood of hospital‑associated VTE to guide need for prophylaxis.

Cardiac failure
No0Yes+2
Respiratory failure
No0Yes+2
Recent stroke (< 3 months ago)
No0Yes+2
Recent myocardial infarction (< 4 weeks ago)
No0Yes+2
Acute infectious disease (including sepsis)
No0Yes+2
Acute rheumatic disease
No0Yes+2
Active malignancy
No0Yes+2
Myeloproliferative syndrome
No0Yes+2
Nephrotic syndrome
No0Yes+2
Any prior VTE
No0Yes+2
Known hypercoagulable state
No0Yes+2
Immobilization for ≥ 3 days (< 30 min of walking per day)
No0Yes+1
Recent travel > 6 hrs
No0Yes+1
Age > 60 years
No0Yes+1
Obesity BMI > 30
No0Yes+1
Chronic venous insufficiency
No0Yes+1
Pregnancy
No0Yes+1
Hormonal therapy (contraceptive or replacement therapy)
No0Yes+1
Dehydration
No0Yes+1

Indications for Use

Used for hospitalized medical inpatients to identify those at elevated VTE risk needing pharmacologic prophylaxis and to avoid prophylaxis in low‑risk patients (external validation across multiple cohorts) 1 [Level II evidence]. Provides moderate discrimination but improves appropriate prophylaxis rates in impact studies 2 [Level II evidence]. Best applied within a risk-adapted prophylaxis strategy when bleeding risk is acceptable.

Insights & Cautions

Start by recognizing limited accuracy: the simplified and original versions show poor discrimination (AUC <0.60) for predicting 90‑day VTE in medical inpatients 1 [Level II evidence]. Use cautiously—high sensitivity but low specificity leads to overclassification, and mobility/infection risk is frequently misjudged. Do not rely on it alone for prophylaxis decisions; integrate clinical judgment and bleeding‑risk assessment, as impact studies show improved prophylaxis rates but modest predictive value 2 [Level II evidence].